In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33524282.
- Also identified by DOI 10.7326/ACPJ202102160-017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pan H, Peto R, Henao-Restrepo AM, et al. <b>Repurposed antiviral drugs for Covid-19-interim WHO Solidarity Trial results.</b> N Engl J Med. 2020. [Epub ahead of print.] 33264556.
Medical subject headings
- Antiviral Agents
- COVID-19
- Hospital Mortality